Answer
Rezurock (belumosudil mesilate) is indicated for patients aged 12 years and older with chronic graft-versus-host disease who have received at least two prior lines of systemic therapy.
Sources for this answer
- REZUROCK 200 mg film-coated tablets.SANOFI · emc · SmPC §4.1 Therapeutic Indications · Version 8Document updated
Sources checked